Annovis Bio Announces Positive FDA Notice For ...
Annovis Bio received FDA approval to proceed with a Phase 3 clinical study of buntanetap for Parkinson's disease, following a successful Type B meeting. The FDA accepted the study's protocol and development plan, allowing longer duration trials. Buntanetap, targeting neurodegenerative diseases, showed significant improvements in Phase 2a trials for Parkinson's and Alzheimer's patients.
Reference News
Annovis Bio received FDA approval to proceed with a Phase 3 clinical study of buntanetap for Parkinson's disease, following a successful Type B meeting. The FDA accepted the study's protocol and development plan, allowing longer duration trials. Buntanetap, targeting neurodegenerative diseases, showed significant improvements in Phase 2a trials for Parkinson's and Alzheimer's patients.